Of note, this enhanced efficacy of CAR(NAP) T cells was neither dependent on the nature of the target antigen, nor the tumour types or host haplotypes, as superior therapeutic efficacy was also observed for CAR(NAP) T cells in various tumour models, including NXS2-mCD19 neuroblastoma (Extended Data Fig. 3), Panc02-mCD19 pancreatic adenocarcinoma (Extended Data Fig. 4) and CT26-hPSCA colon carcinoma (Extended Data Fig. 5). This evidence concerns the gene DDX53 and neuroblastoma.